Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb randomized double-blind placebo-controlled study of ocrelizumab in primary progressive multiple sclerosis
2018-001511-73Phase 3Unknown
- Sponsor
- Roche
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary progressive multiple sclerosis (PPMS) comparing Ocrelizumab arm with Placebo arm (2 arms). Status: unknown.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2018-001511-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001511-73.